Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KF115
- Development stage
- Preclinical
- Lead developer
- Akeso
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
KF115 is an investigational small interfering RNA (siRNA) therapeutic being developed by Akeso, Inc. (also known as Kangfang Biopharma). It represents a strategic expansion for Akeso into the field of RNA interference (RNAi) and non-oncology therapeutic areas, including autoimmune diseases, respiratory disorders, allergies, and central nervous system (CNS) indications. The drug is designed to utilize the endogenous RNAi pathway to silence the expression of specific mRNA transcripts, thereby downregulating the production of proteins associated with disease pathogenesis. As of early 2024, KF115 is in the early stages of development, and its specific biological target remains proprietary and undisclosed.
- Other names
- KF115-Akesios-multispecific antibody-tumorsKF-115-Akesios-multispecific antibody-tumorsKF 115-Akesios-multispecific antibody-tumorsIL-15/IL-15Rα-Fc fusion protein
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on KF115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KF115.